Exploring regulatory data sets of the Comirnaty vaccine - Second part

A summary of posts

In post 9 of the series, we explained our methods for identifying PK data.

Exploring regulatory data sets of the Comirnaty vaccine - 9

and in the following posts, 9a to 9e

Exploring regulatory data sets of the Comirnaty vaccine - 9a

we explained that the PK data seen by regulators lacked numbers and details, for example, with a lack of genotoxicity and carcinogenicity studies. In post 9b, we reported our understanding of the production of the misreported mRNA (alias mmRNA)

Exploring regulatory data sets of the Comirnaty vaccine - 9b

…